EN | JPN | FR
EN | JPN | FR
For over four decades, Ora has led the way in advancing ocular surface disease treatments. Our expertise in trial design, endpoint selection, recruitment, and reducing data variability has fueled multiple product approvals and treatments for Dry Eye Disease.
Conjunctivitis Treatment
George Ousler, Ora’s SVP of Anterior Segment, directs our Dry Eye/Ocular Surface Disease programs, leveraging over
25 years of experience to drive projects from inception to completion. He is at the forefront of creating clinical models and defining regulatory pathways for Dry Eye treatments. Our Anterior Segment Department boasts over 100 professionals collaborating with partners across the US, Europe, and Asia, including key markets like Japan, China,
and South Korea.
George is a prolific contributor to Dry Eye research with over 300 publications and holds multiple patents in the field.
Senior Vice President, Anterior Segment
The Ora Controlled Adverse Environment (CAE®) minimizes influential factors by standardizing temperature, humidity, airflow, lighting, and visual tasking. By creating a constant and reproducible challenge, CAE® offers industry leading precision with fewer patients, fewer sites, and less time.
The CAE® model excels at:
A mobile clinical research platform, built for study success.
The Ora EyeCup™ is a cutting-edge mobile device and app engineered for the success of clinical studies. It allows patients to collect and submit high-resolution ocular images and diary data anytime, anywhere, directly to a web platform.
On-the-go, instantaneous data capture, with detailed ocular imaging and symptom logging.
AI-driven image analysis for accurate evaluation of ocular redness, tear film, and corneal health.
A compliance diary to ensure accurate symptom and medication tracking.
Streamlined protocol adherence, significantly speeding up study timelines.
Easy to use, the Ora EyeCup™ ensures real-time, precise assessment of ocular conditions, whether at home, in a clinic, or during environmental stress tests like the Ora CAE® and Ora BioCube®.
The platform is fully customizable, delivering vital clinical metrics and comprehensive patient feedback.
“When we say we have a certain timeline or a certain budget, Ora is flexible and works to stay in it.”
Charles Bosworth,
Chief Medical Officer
Azura
Ora, Inc websites use cookies. By continuing to browse the site you are agreeing to our use of cookies.
For more details about cookies and their use, please see our Privacy Policy.
